Related Experiment Videos
Perspectives on oncologic imaging with radiolabeled antibodies
1The Center for Molecular Medicine and Immunology, The Garden State Cancer Center, Belleville, New Jersey 07109, USA.
Cancer
|December 24, 1997
Summary
Nuclear imaging, including radioimmunodetection and PET, offers advanced cancer detection and staging. Antibody-based imaging agents also help select patients for targeted therapies, improving cancer management.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiochemistry
Background:
- Nuclear imaging tests are increasingly vital in cancer management, aiding detection, diagnosis, and patient selection for therapy.
- These techniques identify tumors based on their functional characteristics.
Purpose of the Study:
- To review advances and clinical applications of cancer imaging using radiolabeled antibodies (radioimmunodetection).
- To assess the contribution of positron emission tomography (PET) in oncologic practice.
Main Methods:
- Selective review of radioimmunodetection and PET imaging in cancer management.
- Focus on clinical applications in specific cancer types and the use of antibody imaging agents.
Main Results:
- Radioimmunodetection and PET show significant contributions in colorectal, breast, lung cancers, and non-Hodgkin's lymphoma (NHL).
- Agents like OncoScint and CEA-Scan aid in staging and detecting occult lesions in colorectal cancer.
- Antibody imaging offers high specificity, complementing mammography for breast cancer and aiding lung cancer staging.
Conclusions:
- Radioimmunodetection and PET provide enhanced, sensitive functional imaging for early cancer detection.
- Unlike PET, antibody agents can identify patients eligible for antibody-based therapies.